US biosimilars consensus thwarted by three big issues
This article was originally published in Scrip
If US FDA officials had hoped a consensus would emerge when they invited all stakeholders to participate in a two-day meeting 2 and 3 November on how to create a pathway for follow-on biologics to get onto the US market, they were surely disappointed. What the FDA did get, however, was a clear indication from speakers from all sides of pharma, from patient advocate groups, from providers groups and from academia what the major issues the agency must try to finesse in putting into effect the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) Congress passed last year. The statute gives FDA a great amount of freedom in interpreting its provisions.
You may also be interested in...
When AstraZeneca, Pfizer and Takeda, which had been asked by the FDA to conduct trials of their proton-pump inhibitors (PPIs) for treating gastroesophageal reflux disease (GERD) in infants, presented their results, the agency knew it had a problem. None of the trials showed the drugs to be effective. Consequently, the FDA convened a panel of outside experts on 5 November to advise on what it should do next.
If US Food and Drug Administration officials had hoped a consensus would emerge when they invited stakeholders to participate in a two-day meeting on 2 and 3 November on how to create a pathway for follow-on biologics to get onto the US market, they were surely disappointed.
The US FDA's endocrinologic and metabolic drugs advisory committee on January 13 voted unanimously to recommend that the agency approve Recordati's carglumic acid for the treatment of hyperammonaemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS).